SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-148767
Filing Date
2022-05-12
Accepted
2022-05-12 16:46:04
Documents
13
Period of Report
2022-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d273326d8k.htm   iXBRL 8-K 25563
2 EX-99.1 d273326dex991.htm EX-99.1 39792
  Complete submission text file 0001193125-22-148767.txt   203492

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cmpi-20220512.xsd EX-101.SCH 2882
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmpi-20220512_lab.xml EX-101.LAB 19502
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmpi-20220512_pre.xml EX-101.PRE 12174
7 EXTRACTED XBRL INSTANCE DOCUMENT d273326d8k_htm.xml XML 3662
Mailing Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Business Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 978-503-2124
Checkmate Pharmaceuticals, Inc. (Filer) CIK: 0001651431 (see all company filings)

IRS No.: 364813934 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39425 | Film No.: 22918600
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences